AbbVie has an exciting and diverse pipeline of promising new therapies like ABBV-383, a BCMA CD3 bispecific, being studied (in phase III) for relapsed/refractory multiple myeloma and Teliso-V ...

AbbVie Starts Phase III Multiple Myeloma Study on BCMA Therapy, ABBV-383: AbbVie announced that it has initiated a phase III study on ABBV-383, a B-cell maturation antigen (BCMA) bispecific ...

Meanwhile, additional competition could be on the way in the form of AbbVie’s ABBV-383, another BCMAxCD3 bispecific that is in a registrational trial. One possible differentiator is a reduced ...

We continue to make good progress with our BCMA CD3 bispecific ABBV-383 in multiple myeloma. Recruitment is going well in the Phase 3 monotherapy study in later lines, and we are on track to be ...